Division of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Curr Hematol Malig Rep. 2012 Sep;7(3):221-7. doi: 10.1007/s11899-012-0133-2.
Rituximab (R) is a monoclonal antibody with high therapeutic efficacy in low-grade CD20+ lymphoma. The combination of R with chemotherapy is the most common treatment option for patients with follicular lymphoma (FL). The efficacy of R has also been shown to be augmented, when used in combinations with biologicals such as interferon-alpha-2a (IFN), bortezomib, or lenalidomide. The best combination of these drugs are not well defined and a better understanding of pharmacokinetics and timing of drugs relative to the rituximab infusion is crucial. Other new targeted agents, such as inhibitors of BTK and PI3Kdelta, have also been promising in FL. Translational research questions should be added to clinical trial protocols to increase the knowledge on how the tumor microenvironment and the host immune system affect the response to the different drugs and combinations with the aim of a more individualized therapy.
利妥昔单抗（R）是一种在低级别 CD20+淋巴瘤中具有高度治疗疗效的单克隆抗体。R 与化疗联合是滤泡性淋巴瘤（FL）患者最常见的治疗选择。当与生物制剂（如干扰素-α-2a（IFN）、硼替佐米或来那度胺）联合使用时，R 的疗效也得到了增强。这些药物的最佳组合尚未得到很好的定义，因此更好地了解药物的药代动力学和相对于利妥昔单抗输注的时间至关重要。其他新的靶向药物，如 BTK 和 PI3Kdelta 抑制剂，在 FL 中也有很好的疗效。应该在临床试验方案中增加转化研究问题，以增加对肿瘤微环境和宿主免疫系统如何影响不同药物和组合反应的了解，从而实现更个体化的治疗。
